Aurora Cannabis Q4 2026 Earnings Report

Aurora Cannabis EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.07
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aurora Cannabis Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $54.42 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aurora Cannabis Announcement Details

• Quarter: Q4 2026
• Date: 6/17/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, June 17, 2026
• Conference Call Time: 9:30AM ET

Aurora Cannabis (NASDAQ:ACB) (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments. Aurora serves both the medical market—with products distributed through physicians and pharmacies—and the adult‐use market in jurisdictions where recreational cannabis is legal. Its portfolio includes proprietary genetics and branded offerings designed to deliver consistent cannabinoid and terpene profiles.

Aurora operates several state-of-the-art production facilities, including high-tech greenhouses and indoor cultivation sites, most notably the Aurora Sky campus near Edmonton. The company holds EU Good Manufacturing Practice (GMP) certification, enabling exports to key European markets such as Germany, Italy and Denmark, and maintains partnerships in Latin America, Australia and parts of the Asia Pacific region. Through strategic investments and acquisition of international distribution platforms, Aurora seeks to extend its reach into emerging cannabis markets.

Leadership at Aurora Cannabis has evolved since its founding, with Chairman and Chief Executive Officer Miguel Martin overseeing a shift toward operational efficiency and product innovation. The company’s early leadership team included co-founders Terry Booth and Steve Dobler, who guided initial expansion and public-market entry. Aurora has also pursued notable acquisitions—such as MedReleaf in 2018—to bolster production capacity and diversify its product mix. Looking ahead, Aurora aims to leverage its research capabilities and global infrastructure to capture growth opportunities in both medical and adult-use cannabis sectors.